venBio Select Advisor LLC 4
4 · IMMUNOMEDICS INC · Filed Sep 18, 2018
Insider Transaction Report
Form 4
IMMUNOMEDICS INCIMMU
Aghazadeh Behzad
Director10% OwnerOther
Transactions
- Award
Common Stock, $0.01 par value per share
2018-04-02+3,849→ 3,849 total - Award
Stock Options (right to buy)
2018-04-02+6,497→ 6,497 totalExercise: $14.29From: 2019-04-02Exp: 2025-04-02→ Common Stock, par value $0.01 per share (6,497 underlying)
Holdings
- 17,714,461(indirect: See footnotes)
Common Stock, $0.01 par value per share
Footnotes (5)
- [F1]Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018.
- [F2]Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Behzad Aghazadeh's ("Dr. Aghazadeh") continued service as a director of the Issuer.
- [F3]The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Dr. Aghazadeh (together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
- [F4]The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
- [F5]The stock options vest on the first anniversary of the date of grant, subject to the Dr. Aghazadeh's continued service as a director of the Issuer.